Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights ...
(PR-inside.com) Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities RALEIGH, NC / ACCESS Newswire / November 6, 2026 / Vogenx, Inc. (NASDAQ:VOGX), a clinical-stage developer of novel therap…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


